Brought to you by 
Immunocore signs on Genentech as first major partner to develop ImmTACs; expanded
16 Nov 2021
Executive Summary
Roche’s Genentech Inc. has licensed rights to discover, develop, and market UK immunotherapeutics firm Immunocore Ltd.’s biologic candidates called ImmTACs (Immune mobilizing mTCR Against Cancer) directed at several novel oncology targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immunocore signs on Genentech as first major partner to develop ImmTACs; expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice